Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | PHASE3 | RECRUITING | 20 | — | — | Feb 1, 2026 | Dec 1, 2026 | Feb 11, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Induction/Consolidation/Maintenance (ICM) ADX-2191 injection | EXPERIMENTAL | - |
| Monthly ADX-2191 injection | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ICM ADX-2191 injection | DRUG | Following the development of lymphomatous vitreous cells in at least one eye, subjects will follow ICM dosing with ADX-2191 intravitreal injections twice weekly for four weeks, followed by weekly for eight weeks, for a total of sixteen injections. |
| Monthly ADX-2191 injection | DRUG | Following the development of lymphomatous vitreous cells in at least one eye, subjects will dose monthly with ADX-2191 intravitreal injections for a total of three injections. Sham injections will be performed for those visits during which ADX-2191 is not injected, for a total of thirteen sham injections. |
Inclusion Criteria: 1. 21 years old or older; of any gender 2. Biopsy proven primary vitreoretinal lymphoma 3. Presence of lymphomatous vitreous cells at the Screening Visit and/or any eye that has been vitrectomized to confirm the diagnosis of primary vitreoretinal lymphoma 4. Willingness to parti...